Company intelligence / Profile preview

New Horizon Health

Hangzhou, Zhejiang Province, 中国horizonmedicare.co.uk ↗

Ownership: Private
Development stage: Commercial

Overview

New Horizon Health develops and commercializes non-invasive early-stage cancer screening tests. Its flagship product ColoClear is approved and marketed for colorectal cancer screening in China. The company also markets Pupu Tube for fecal occult blood self-testing and UU Tube for Helicobacter pylori detection. There have been recent allegations regarding financial reporting; an independent forensic investigation is ongoing as of mid-2025, with trading on the Hong Kong Stock Exchange suspended since March 2024.

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

3 assets

ColoClear

Commercial

Indications: Colorectal cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on New Horizon Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Horizon Health.

Explore the full profile